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Stroke prevention in atrial fibrillation 
 
Atrial fibrillation (AF) is the most common arrhythmia with over 1 million people 
diagnosed in the United Kingdom (UK).1-3 It can lead to ischaemic stroke, which is 
one of the biggest causes of death in England and has annual health and social 
cares costs of £4.38billion in the UK.4 Ischaemic strokes associated with AF have 
poorer outcomes with a higher mortality and greater disability5, yet strokes 
associated with AF are mainly preventable. It is estimated that 7,000 strokes and 
2,000 premature deaths each year could be prevented with oral anticoagulants in 
England.6 Warfarin can reduce the risk of stroke by 64%7 and direct oral 
anticoagulants (DOACs) were shown to be as effective as warfarin in the prevention 
of ischaemic stroke.8 
 
Warfarin and DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are 
recommended by NICE for stroke prevention in non-valvular AF (SPAF). Aspirin 
monotherapy should not be used for SPAF as it is considerably less effective than 
warfarin or DOAC7,9 and possesses similar bleeding risks to warfarin.10 All patients 
with AF and CHA2DS2-VASc score of 2 or more should be offered oral 
anticoagulants unless there is an absolute contraindication. Anticoagulation is not 
indicated to very low risk of stroke patients with AF, i.e. under 65 years of age and 
no risk factors other than their sex.9  
 
Nationally, 22% of people with AF and CHA2DS2-VASc score of 2 or more are still 
not anticoagulated according to the latest Quality Outcome Framework (QOF) data11 
and 1/3 of patients are inadequately treated with aspirin monotherapy.6 There has 
been a gradual increase in the levels of anticoagulation which seems to be 
unaffected by the removal of aspirin from the guidelines or the increase in 
therapeutic options available (Figure 1).12-15  The latest national stroke audit data 
shows that only 54% patients with AF admitted for stroke between August 2016 and 
November 2016 were taking oral anticoagulants. Almost one fifth of patients were 
taking antiplatelet only, such as aspirin, despite it being removed from the NICE 
guideline and QOF more than a year ago.15 
 
Barriers for initiating oral anticoagulants for SPAF 
  
The perceptions of clinicians about risks associated with oral anticoagulants can 
prevent the initiation of oral anticoagulation therapy. Clinicians, including general 
practitioners (GPs), have been shown to be reluctant to initiate oral anticoagulants in 
patients with advanced age, especially in older than 80 years, despite them being 
healthy and without contraindications to oral anticoagulation.16,17 Age on its own 
should not be a contraindication to anticoagulation as older patients (>75 years) are 
at higher risk of stroke and have greater benefit from the intervention.9,16,17 The 
reluctance to prescribe oral anticoagulants to patients with advanced age is followed 
by overestimation of the bleeding risk.16 Treatment is often withheld in elderly due to 
concerns over excessive bleeding risk17, despite the net clinical benefit of oral 
anticoagulants increasing with age and being the highest among 85 years and older 
patients.18 
 
There is no consensus amongst clinicians what risk of bleeding is acceptable with 
oral anticoagulants.16,19 Clinicians were significantly less likely to prescribe oral 
anticoagulants to new patients after their previous patient had a major bleeding 
adverse event associated with anticoagulation.20 Surprisingly, occurrence of 
ischaemic stroke in non-anticoagulated patient with AF did not increase the use of 
oral anticoagulants in physician’s future patients.20 The perception of bleeding and 
stroke risks differs between physicians and patients. Patients at high risk of 
developing AF were happy to accept a much higher risk of bleeding in order to avoid 
stroke compared to primary and secondary care clinicians.19 This means that 
patients should always be involved in shared-decision making about whether to 
prescribe or not (see below). 
 
Falls with risk of intracranial bleeding were cited as a reason to withhold oral 
anticoagulants.17 Clinicians perceive that elderly patients will be at the increased risk 
of falls and thus increased risk of bleeding and therefore oral anticoagulants are not 
initiated. However, patients would need to fall around 300 times per year for risks of 
intracranial bleeding to outweigh the benefits of oral anticoagulants.21 The reported 
annual sustained falls rate for elderly patients is only 1.81.22 The bleeding risk should 
be calculated using validated tools such as HAS-BLED.9 A high HAS-BLED score is 
not a reason to withhold treatment with oral anticoagulants; it should be used as a 
tool to correct modifying bleed risks such as high blood pressure; co-prescribing of 
gastric irritant drugs such as corticosteroids and NSAIDs and drugs with antiplatelet 
effects such as SSRIs, aspirin, ticagrelor, prasugrel and clopidogrel for instance. 
 
Meta-analysis of DOACs studies showed significantly lower rates of intracranial 
bleeding, similar major bleeding but higher gastrointestinal bleeding rates when 
compared with warfarin.23 DOACs overcome some of the barriers reported with 
warfarin use (extensive food and drug interactions, frequent monitoring 
requirements)9,24 but some clinicians have been shown to be resilient to initiate them 
by citing the lack of a reversal agent in a major bleeding event.24 The rapid onset of 
 DOACs diminishes the need of antidote in most situations. However, in certain 
situations such as life-threatening bleed or urgent surgery a reversal agent could be 
beneficial. There is currently a licensed reversal agent for dabigatran called 
idarucizumab25 and several others are in the pipeline.26 
 
Lack of experience is another key factor in preventing prescribing of oral 
anticoagulants for SPAF. A study interviewing GPs, practice managers, and nurses 
observed that majority of oral anticoagulation for SPAF was initiated in secondary 
care and hence primary care staff, including GPs, felt a lack of experience in starting 
anticoagulation.27 Inadequate communication between primary and secondary care 
was highlighted as another barrier.27  
 
Prescribing behaviour of GPs is also influenced by secondary care specialists, 
consultants, clinical investigators, and peers.28-32 Organisational barriers to the use 
of oral anticoagulants, especially DOACs, are less well described in the literature. 
Cost of DOACs is perceived as a barrier for their use. However, NICE concluded that 
they are cost-effective and should be made available locally in line with their 
guidance without additional funding and formulary restrictions.9 Locally, Clinical 
Commissioning Groups (CCGs) are responsible for the medicine management in 
their areas and can adapt medicine management processes to local area needs.33 
But should follow NICE recommendations which state that warfarin or DOACs can 
be considered for newly diagnosed patients, patients inadequately managed with 
warfarin, and  patients taking aspirin and thus should be made available locally.9 
 
Shared-decision making 
 
Patient-centred care is at the heart of the NHS and patients should be fully informed 
about their treatment options.34 Patients with AF requiring anticoagulation wish to be 
involved in the shared decision-making about oral anticoagulation35-38 even in 
situations when they defer decisions to clinicians.35-37 Patients also want to receive 
new information after making the decision and it is important for them to be able to 
discuss their options again with the clincian.35 This observation is important since 
four DOACs have been introduced for SPAF and patients already taking warfarin 
should be offered a choice of changing oral anticoagulant, if appropiate.9 However, 
the literature shows that patients have little or no say in such decisions.35,39,40 NICE 
has produced a patient decision aid to help patients to make informed decisions 
about taking oral anticoagulants.41  
 
Initiation and monitoring of DOACs 
 
Historically many GPs have been reluctant to initiate DOACs as they did not 
consider themselves to have sufficient expertise. Currently initiation is most often 
undertaken, or recommended, by specialists and GPs with a special interest. 
However GPs are increasingly initiating DOACs and as they are expected to 
 continue the prescribing of DOACs started by others they need to have knowledge 
and skills to prescribe and monitor.  
 
Initiation9,42 
NICE recommend that anticoagulation should be: 
 
 Considered for men with a CHA2DS2-VASc score of 1, taking the bleed risk 
into account 
 Offered to people with a CHA2DS2-VASc score of 2 or above, taking bleed 
risk into account. 
 
Firstly, any absolute contraindications to anticoagulation should be identified, as 
these patients cannot be offered treatment. However individual circumstances may 
change over time so periodic reassessment is recommended. The number of 
absolute contraindications is relatively small (Table 1). 
 
There are a number of relative contraindications to oral anticoagulants (Table 2) and 
the decision as to whether to offer treatment should take these into consideration.  
 
Where treatment can be offered patients must be involved in the decision. Patients 
need to know that DOACs, like warfarin, are potent anticoagulants so the same risks 
of minor and major bleeding still apply. The anticoagulant effects of DOACs wear off 
quickly (next day). This means that if patients miss a dose then they will not have 
anticoagulant cover and will be at increased risk of a stroke. 
 
Before starting treatment modifiable risk factors should be managed such as 
controlling systolic blood pressure to < 160mmHg and stopping gastric irritant 
medicines such as NSAIDS, and if possible antiplatelet and interacting drugs.  
 
Before starting a DOAC necessary tests should be up to date (kidney function; liver 
function, full blood count and clotting screen). Life-style modifications should also be 
discussed with the patient such as reducing alcohol intake or moderating drinking, if 
applicable. Patient should be referred to the community pharmacist for a New 
Medicines Review and be given an anticoagulant warning card to carry at all times.
 A checklist for initiation of anticoagulants is given in the Table 3:  
 
Monitoring until patient stable 
 
Monitoring is recommended to occur every 3 months to assess adherence 
and to reinforce advice regarding regular dosing schedule and also to enquire 
about adverse effects such as bleeding.42 Patients should be assessed for the 
presence of thromboembolic events and enquiries made about other 
medicines the patient is taking, including OTC medicines. 
Ongoing monitoring 
Recall systems should be set up for monitoring of DOACs. Recalls can be set 
up on GP systems such as TPP SystmOne and EMIS, or software such as 
INR STARN3 can also be used.  
Monitoring parameters are shown in the Table 4. The frequency of monitoring 
is consensus based. This guidance is based on advice from manufacturers 
and Clinical Knowledge Summaries guidance.  
Bleed risk needs to be managed both at initiation of a DOAC and on an on-
going basis, e.g. BP needs to be managed, alcohol intake should be limited 
and all gastric irritant drugs such as SSRI and antidepressants need to be 
reviewed. A proton pump inhibitor can be offered on initiation of a DOAC if felt 
appropriate, especially if also prescribed gastric irritant drugs which can’t be 
stopped. 
Summary 
Strokes due to AF are effectively prevented with warfarin or DOACs. 
Anticoagulation in AF is still underused and one third of patients are 
inadequately treated with aspirin, despite the strong evidence and introduction 
of DOACs. The slow uptake of DOACs has been a result of a number of 
behaviour and organisation barriers. The net clinical benefit of oral 
anticoagulants increases with age and is the highest among older patients 
perceived to be at high risk of bleeding and falls. Tools like HAS-BLED can be 
used to calculate the risk of bleeding and identify modifiable factors for 
correction rather than used as a stop tool for oral anticoagulation. Patients 
may have different perspectives on bleeding risks and accept higher risk than 
clinicians in order to prevent disabling and debilitating strokes but their 
involvement is not always facilitated in the shared-decision making. The 
offered choice of oral anticoagulant should follow national guidelines. 
Identified patients at risk of AF related stroke and patients inadequately 
anticoagulated with aspirin should be prescribed warfarin or a DOAC after 
discussion with the patient and consideration of risk and benefits. Education 
 of both patients and prescribers continue to be a vital aspect in overcoming 
barriers to oral anticoagulants for SPAF. GPs need to be provided with tools 
and support to confidentially and safely prescribe and monitor DOACs.  
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  A significant risk of major bleeding such as: 
o Current  gastrointestinal ulcer. 
o Recent brain or spinal injury. 
o Recent brain, spine, or ophthalmic surgery. 
o Recent intracranial haemorrhage. 
o Malignant neoplasm. 
o Vascular aneurysm. 
 A prosthetic heart valve. 
 Liver disease associated with coagulopathy and clinically relevant bleeding 
risk, as well as people who have cirrhosis with Child-Pugh grade B (moderate 
impairment) or grade C (severe impairment). 
 Significant thrombocytopenia (platelet count < 50 x 109/L) - refer to 
haematologist.  
 Within 72 hours of major surgery with risk of severe bleeding - defer & 
reassess risk postoperatively.  
 Previously documented hypersensitivity to either the drug or excipients – 
consider cardiology opinion.  
 Acute clinically significant bleed - defer & re-assess stroke versus bleeding 
risk within 3 months.  
 Pregnancy, breast feeding or within 48hours post-partum - seek urgent 
haematological/obstetric/cardiology advice.  
 Certain co-prescribed medicines (see summary of product characteristics) 
 Severe renal impairment 
o CrCl <30ml/min avoid dabigatran  
o CrCl<15ml/min: avoid all DOACs  
o On dialysis 
 
Table 1. Absolute contraindications to DOACs.42-47 
 
 
 Recent history of recurrent iatrogenic falls in patient at higher bleeding risk.  
A patient at higher bleeding risk is assessed by having 3 or more of the 
following risk factors:-  
o Age > 65 years  
o Previous history bleed or predisposition to bleeding (e.g. diverticulitis)  
o Uncontrolled hypertension  
o Severe renal impairment (i.e. serum creatinine > 200umol/L, GFR < 30 
mL/min/1.73m
2 
or on dialysis)  
o Acute hepatic impairment (e.g. bilirubin > 2xULN + LFTS > 3x ULN), 
chronic liver disease (e.g. cirrhosis)  
o Low platelet count < 80 x 109/L or a thrombocytopenia or anaemia of 
undiagnosed cause 
o On concomitant drugs associated with an increased bleeding risk, e.g. 
SSRIs, oral steroids, NSAIDs, methotrexate or other immune-
suppressant agents.  
 Previous history intracranial haemorrhage - as some AF patients especially 
 those considered at higher stroke risk may benefit from anti-thrombotic 
therapy, seek the opinion of a stroke specialist.  
 Recent major extracranial bleed within the last 6 months where the cause has 
not been identified or treated – decision for oral anti-thrombotic therapy 
should be deferred.  
 Recent documented peptic ulcer (PU) within last 3 months– decision for oral 
anti-thrombotic therapy should be deferred until treatment for PU completed. 
In all cases with history PU give PPI cover whilst on anti-thrombotic.  
 Dementia or marked cognitive impairment with poor medicines compliance 
and no access to carer support.  
 Chronic alcohol abuse – especially if associated with binge drinking. 
 
Table 2. Relative Contraindications to DOACs.42-47 
 
 
 
 
• Assess the patient’s understanding of the risks and benefits of treatment and their desire to take the treatment and to 
attend for ongoing monitoring. 
• Assess the patient’s ability to adhere to the prescription and monitoring of treatment. 
• Check kidney function ((U+Es) may need dose reduction or avoidance of certain NOACs), body weight (underweight may 
need dose reduction of NOAC), baseline clotting screen, FBC, LFTs, blood pressure values recorded in last 6 months will be 
okay to use unless patients has been acutely  ill  since. 
• Check for any absolute contraindications  
• Check for any relative contraindications and determine if benefits likely to outweigh the risks  
•  Identify and manage modifiable risk factors to reduce bleed risk i.e. manage blood pressure, stop NSAIDs and if possible 
SSRI antidepressants  and antiplatelets.  Consider co-prescribing of PPIs. 
 
 
• Discuss patient life-style changes that will reduce bleed risk e.g. cutting back on alcohol 
 
 
• Choose the drug and dose that is best for the patient e.g. a lower dose will be needed for reduced kidney function 
• Ensure INR is at correct value before changing to a DOAC from warfarin (see summary of product characteristics) 
 
 
• Set up a recall system for monitoring treatment 
  
Table 3. Checklist before starting a DOAC. 
 
Adherence Ideally 3 monthly (otherwise 6 monthly) 
Bleed risk Ideally 3 monthly (otherwise 6 monthly) 
Liver function tests Annually 
Full blood count Annually 
Kidney function CrCl >60ml/min annually  
CrCl 30-60ml/min 6 monthly  
CrCl 15-30ml/min 3 monthly*  
Table 4. Guidance on ongoing monitoring of DOACs.42-45 
*Dabigatran treatment is contraindicated if CrCl < 30ml/min. Monitor 
U&E’s/LFTs more frequently if inter-current illness  
European guidance states that creatinine clearance, calculated using the 
Cockcroft & Gault equation, needs to be used when checking for correct 
dosing when monitoring DOACs.  
 
 
 
